
Cell Line Data Sheet for CHLA-200

Disease: Glioblastoma Multiforme
Phase of Therapy: Post-Chemotherapy (Progressive Disease), Post-mortem
Treatment: Multiple recurrences treated with chemotherapy and radiation
Disease Stage: 4
Gender: Male
Age at diagnosis: 144 months
Race: NA
Age at sample collection: NA
Source of Culture: Tumor (parietal lobe)
Primary Tumor Site: NA
Date Established: November 1997

MYCN Patient: Non-Amplified
MYCN Cell line: Relative copy number - NA
TH mRNA: NA
p53 functionality: Silent TP53 polymorphism at exon 6 codon 213 (GCA to CGG)
Telomere Mechanism NA
ALK: NA
RNAseq: NA
WES: NA

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 54 hours

Growth Properties: Adherent monolayer

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: None

All cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for CHLA-200

Cell Line Name: CHLA-200

References:

1. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology. Epub,



Cell Line Data Sheet for CHLA-200

Cell Line Name: CHLA-200

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)